Categories: Health

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Taysha Gene Therapies, Inc.

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted one new employee an option to purchase 90,000 shares of the Company’s common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.63 which is equal to the closing price of Taysha’s common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee’s continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

GlobeNews Wire

Recent Posts

UAE Breaks Ground on World’s First Gigascale Round-the-Clock Renewable Energy Project, Setting a New Global Standard For Clean Energy

In line with the vision of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of…

1 minute ago

WSPN Launches Checkout: Bringing Stablecoin Payment Infrastructure to E-Commerce

TORTOLA, British Virgin Islands, Oct. 24, 2025 /PRNewswire/ -- Worldwide Stablecoin Payment Network (WSPN), a leading…

1 minute ago

Bybit Enhances Capital Mobility for VIP and Institutional Traders with Expanded Withdrawal Limits

DUBAI, UAE, Oct. 24, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume,…

4 hours ago

Bybit TradFi Launches Referral Program Offering Up to 30% in Rewards

DUBAI, UAE, Oct. 24, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading…

4 hours ago

CGTN: Restoring the History of Taiwan

BEIJING, Oct. 25, 2025 /PRNewswire/ -- Men forget, and history overlooks. But history is not,…

5 hours ago

Shanghai Electric Signs Parau Phase II 342 MW PV Project with Econergy, Supporting Romania’s Green Future

As Shanghai Electric's fourth photovoltaic project in Romania, this initiative marks a major step forward…

5 hours ago